File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia - 1-year results of a prospective series

TitlePhotodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia - 1-year results of a prospective series
Authors
Issue Date2005
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/eye
Citation
Eye, 2005, v. 19 n. 8, p. 834-840 How to Cite?
AbstractPurpose: To study the efficacy of photodynamic therapy (PDT) with verteporfin in the treatment of juxtafoveal choroidal neovascularization (CNV) secondary to pathologic myopia. Methods: Prospective, open label, two-centre, noncomparative, interventional case series. Consecutive patients with juxtafoveal CNV associated with pathologic myopia were recruited and treated with a standard regimen of PDT with verteporfin. Patients were being followed up every 3-monthly and retreatment was considered when there was evidence of angiographic leakage. Outcome measures included changes in the mean best-corrected visual acuity (BCVA) at the 1-year follow-up when compared with the baseline, the proportion of patients who had stable (within 1 line) and improved visions. Results: A total of 11 eyes from 11 patients with juxtafoveal CNV secondary to pathologic myopia were recruited and all completed the 1-year follow-up. The mean age at presentation was 44.8 years. The refractive error ranged from -6.0 to -15.0 D (± SD was -9.55 ± 3.04D). The logMAR BCVA improved from 0.57 to 0.39 at the 1-year follow-up (Wilcoxon signed-ranks test, P = 0.027). The mean improvement was 1.8 lines. Five eyes (45.4%) had BCVA improved by ≥3 lines. None of the treated patients had visual loss of ≥1 line. The mean number of treatments over the 12-month study period was 2.3 sessions. Conclusions: The results are encouraging, especially on considering the low retreatment rate, stable or improved BCVA in all treated eyes, and consistently good safety profile. Juxtafoveal myopic CNV may be an expanded indication for PDT with verteporfin. © 2005 Nature Publishing Group All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/176425
ISSN
2015 Impact Factor: 2.213
2015 SCImago Journal Rankings: 1.132
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, DSCen_US
dc.contributor.authorLiu, DTLen_US
dc.contributor.authorFan, DSPen_US
dc.contributor.authorLai, WWen_US
dc.contributor.authorSo, SFen_US
dc.contributor.authorChan, WMen_US
dc.date.accessioned2012-11-26T09:11:12Z-
dc.date.available2012-11-26T09:11:12Z-
dc.date.issued2005en_US
dc.identifier.citationEye, 2005, v. 19 n. 8, p. 834-840en_US
dc.identifier.issn0950-222Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/176425-
dc.description.abstractPurpose: To study the efficacy of photodynamic therapy (PDT) with verteporfin in the treatment of juxtafoveal choroidal neovascularization (CNV) secondary to pathologic myopia. Methods: Prospective, open label, two-centre, noncomparative, interventional case series. Consecutive patients with juxtafoveal CNV associated with pathologic myopia were recruited and treated with a standard regimen of PDT with verteporfin. Patients were being followed up every 3-monthly and retreatment was considered when there was evidence of angiographic leakage. Outcome measures included changes in the mean best-corrected visual acuity (BCVA) at the 1-year follow-up when compared with the baseline, the proportion of patients who had stable (within 1 line) and improved visions. Results: A total of 11 eyes from 11 patients with juxtafoveal CNV secondary to pathologic myopia were recruited and all completed the 1-year follow-up. The mean age at presentation was 44.8 years. The refractive error ranged from -6.0 to -15.0 D (± SD was -9.55 ± 3.04D). The logMAR BCVA improved from 0.57 to 0.39 at the 1-year follow-up (Wilcoxon signed-ranks test, P = 0.027). The mean improvement was 1.8 lines. Five eyes (45.4%) had BCVA improved by ≥3 lines. None of the treated patients had visual loss of ≥1 line. The mean number of treatments over the 12-month study period was 2.3 sessions. Conclusions: The results are encouraging, especially on considering the low retreatment rate, stable or improved BCVA in all treated eyes, and consistently good safety profile. Juxtafoveal myopic CNV may be an expanded indication for PDT with verteporfin. © 2005 Nature Publishing Group All rights reserved.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/eyeen_US
dc.relation.ispartofEyeen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshChoroidal Neovascularization - Drug Therapy - Etiology - Physiopathologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMyopia, Degenerative - Complicationsen_US
dc.subject.meshPhotochemotherapy - Adverse Effects - Methodsen_US
dc.subject.meshPhotosensitizing Agents - Therapeutic Useen_US
dc.subject.meshPorphyrins - Therapeutic Useen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshVisual Acuityen_US
dc.titlePhotodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia - 1-year results of a prospective seriesen_US
dc.typeArticleen_US
dc.identifier.emailLai, WW: wicolai@hku.hken_US
dc.identifier.authorityLai, WW=rp00531en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1038/sj.eye.6701681en_US
dc.identifier.pmid15375364-
dc.identifier.scopuseid_2-s2.0-23944448607en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-23944448607&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume19en_US
dc.identifier.issue8en_US
dc.identifier.spage834en_US
dc.identifier.epage840en_US
dc.identifier.isiWOS:000231019800003-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLam, DSC=35500200200en_US
dc.identifier.scopusauthoridLiu, DTL=8550730100en_US
dc.identifier.scopusauthoridFan, DSP=7202965663en_US
dc.identifier.scopusauthoridLai, WW=7402231098en_US
dc.identifier.scopusauthoridSo, SF=8542282300en_US
dc.identifier.scopusauthoridChan, WM=7403914485en_US
dc.identifier.citeulike241794-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats